Preliminary analysis of genomic abnormalities in canine meningiomas

Veterinary and Comparative Oncology

Volumn 6, Issue 3, 2008, Pages 182-192

  Courtay Cahen, C ^a   Platt, S R ^a   De Risio, L ^a   Starkey, Mike P ^a  

^a ANIMAL HEALTH TRUST   (United Kingdom)

Author keywords

Chromosome abnormalities; Comparative genomic hybridization; Dog; Meningioma

Indexed keywords

CANIS FAMILIARIS;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHROMOSOME ABERRATION; DOG; DOG DISEASE; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; MALE; MENINGIOMA; METABOLISM; PHYSIOLOGY;

ANIMALS; CHROMOSOME ABERRATIONS; DOG DISEASES; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; MALE; MENINGIOMA;

EID: 63849169095     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2008.00159.x     Document Type: Article

References (55)

1. Snyder JM, Shofer FS, Van Winkle TJ and Massicotte C. Canine intracranial primary neoplasia: 173 cases (1986 -2003) Journal of Veterinary Internal Medicine 2006; 20: 669-675.
2. Summers BA, Cummings JF and de Lahunta A. Tumors of the central nervous system. In: Veterinary Neuropathology, St Louis, Mosby, 1995: 362-373.
3. Louis DN, Scheithauer BW, Budka H, von Deimling A and Kepes JJ. Meningiomas. In: Pathology and Genetics of Tumours of the Nervous System, 2nd edn., P Kleihues and WK Cavanee, eds., Lyon, IARC Press, 2000: 176-189.
4. Koestner A, Bilzer T, Fatzer R, Schulman FY, Summers BA and Van Winkle TJ. In: Histological Classification of Tumors of the Nervous System of Domestic Animals, Washington DC, Armed Forces Institute of Pathology, World Health Organization, 1999: 27-29.
5. Montoliu P, Añor S, Vidal E and Pumarola M. Histological and immunohistochemical study of 30 cases of canine meningioma. Journal of Comparative Pathology 2006; 135: 200-207.
6. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P and Tortosa A. Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology 2007; 27: 114-120.
7. Maeda H, Shibuya H, Suzuki K, Kuwabara M, Tsukise A and Sato T. A case of anaplastic meningioma in a dog. The Journal of Veterinary Medical Science 2005; 67: 1177-1180.
8. Barnhart KF, Wojcieszyn J and Storts RW. Immunohistochemical staining patterns of canine meningiomas and correlation with published immunophenotypes. Veterinary Pathology 2002; 39: 311-321.
9. Platt SR, Scase TJ, Adams V, Wieczorek L, Miller J, Adamo F and Long S. Vascular endothelial growth factor expression in canine intracranial meningiomas and association with patient survival. Journal of Veterinary Internal Medicine 2006; 20: 663-668.
10. Theon AP, Lecouteur RA, Carr EA and Griffey SM. Influence of tumor cell proliferation and sex-hormone receptors on effectiveness of radiation therapy for dogs with incompletely resected meningiomas. Journal of the American Veterinary Medical Association 2000; 216: 701-707.
11. Mandara MT, Ricci G, Rinaldi L, Sarli G and Vitellozzi G. Immunohistochemical identification and image analysis quantification of oestrogen and progesterone receptors in canine and feline meningioma. Journal of Comparative Pathology 2002; 127: 214-218.
12. Mihaila D, Jankowski M, Gutierrez JA, Rosenblum ML, Newsham IF, Bogler O and Rempel SA. Meningiomas: Loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival. Clinical Cancer Research 2003; 9: 4443-4451.
13. Maillo A, Orfao A, Sayagues JM, Diaz P, Gomez-Moreta JA, Caballero M, Santamarta, D, Santos-Briz A, Morales F and Tabernero MD. New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology. Journal of Clinical Oncology 2003; 21: 3285-3295.
14. Tabernero MD, Espinosa AB, Maillo A, Sayagues JM, Alguero Mdel C, Lumbreras E, Diaz P, Goncalves JM, Onzain I, Merino M, Morales F and Orfao A. Characterization of chromosome 14 abnormalities by interphase in situ hybridization and comparative genomic hybridization in 124 meningiomas: Correlation with clinical, histopathologic, and prognostic features. American Journal of Clinical Pathology 2005; 123: 744-751.
15. Sulman EP, Dumanski JP, White PS, Zhao H, Maris JM, Mathiesen T, Bruder C, Cnaan A and Brodeur GM. Identification of a consistent region of allelic loss on 1p32 in meningiomas: Correlation with increased morbidity. Cancer Research 1998; 58: 3226-3230.
16. Pierotti MA, Schichman SA, Sozzi G, and Croce CM. Mechanisms of oncogene activation. In: Cancer Medicine, 6th edn., RC Bast Jr, DW Kufe, RE Pollock, RR Weichselbaum, JF Holland, E Frei III and TS Gansler, eds., Hamilton, Ontario, Decker Inc., 2003: 73-85.
17. Park BH and Vogelstein B. Tumor-suppressor genes. In: Cancer Medicine, 6th edn., RC Bast Jr, DW Kufe, RE Pollock, RR Weichselbaum, JF Holland, E Frei III and TS Gansler, eds., Hamilton, Ontario, Decker Inc, 2003: 87-105
18. Dumanski JP, Carlbom E, Collins VP and Nordenskjold M. Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma. Proceedings of the National Academy of Sciences USA 1987; 84: 9275-9279.
19. Ruttledge MH, Xie YG, Han FY, Peyrard M, Collins VP, Nordenskjold M and Dumanski JP. Deletions on chromosome 22 in sporadic meningioma. Genes Chromosomes Cancer 1994a; 10: 122-130.
20. Weber RG, Bostrom J, Wolter M, Baudis M, Collins VP, Reifenberger G and Lichter P. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: Towards a genetic model of meningioma progression. Proceedings of the National Academy of Sciences USA 1997; 94: 14719-14724.
21. Carlson KM, Bruder C, Nordenskjold M and Dumanski JP. 1p and 3p deletions in meningiomas without detectable aberrations of chromosome 22 identified by comparative genomic hybridisation. Genes Chromosomes Cancer 1997; 20: 419-424.
22. Lekanne Deprez, RH, Riegmann PH, van Drunen E, Warringa UL, Groen NA, Stefanko SZ, Koren JW, Avezaat CJJ, Mulder GH, Zwarthoff EC and Hagemeijer A. Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas. Journal of Neuropathology and Experimental Neurology 1995; 54: 224-235.
23. Ozaki S, Nishizaki T, Ito H and Sasaki K. Comparative genomic hybridisation analysis of genetic alterations associated with malignant progression of meningioma. Journal of Neurooncology 1999; 41: 167-174.
24. Rempel SA, Schwechheimer K, Davis RL, Cavenee WK and Rosenblum ML. Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Cancer Research 1993; 53: 2386-2392.
25. Simon, M, von Deimling, A, Larson, JJ, Wellenreuther, R, Kaskel, P, Waha, A, Warnick, RE, Tew JM and Menon AG. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: A genetic model of meningioma progression. Cancer Research 1995; 55: 4696-4701.
26. Thomson SAM, Kennerly E, Olby N, Mickelson JR, Hoffmann DE, Dickinson PJ, Gibson G and Breen M. Microarray analysis of differentially expressed genes of primary tumors in the canine central nervous system. Veterinary Pathology 2005; 42: 550-558.
27. Brearley, MJ, Jeffery, ND, Phillips, SM and Dennis, R. Hypofractionated radiation therapy of brain masses in dogs: A retrospective analysis of survival of 83 cases (1991-1996). Journal of Veterinary Internal Medicine 1999; 13: 408-412.
28. National Cancer Institute, U.S. National Institutes of Health (2007). http://www.cancer.gov/cancertopics/pdq/levels-evidence-adult-treatment [accessed 1 August 2007].
29. Courtay-Cahen C, Morris JS and Edwards PA. Chromosome translocations in breast cancer with breakpoints at 8p12. Genomics 2000; 66: 15-25.
30. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F and Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258: 818-821.
31. Sambrook J, Fritsch EF and Maniatis T. Molecular Cloning, a Laboratory Manual, New York, NY, Cold Spring Harbor Laboratory Press, 1989.
32. Courtay-Cahen C, Griffiths LA, Hudson R and Starkey M. Extensive coloured identification of dog chromosomes to support karyotype studies: the colour code. Cytogenetic and Genome Research 2007; 116: 198-204.
33. Breen M, Bullerdiek J and Langford CF. The DAPI banded karyotype of the domestic dog generated using chromosome-specific paint probes. Chromosome Research 1999; 7: 401-406.
34. Thomas R, Smith KC, Ostrander EA, Galibert F and Breen M. Chromosome aberrations in canine multicentric lymphomas detected with comparative genomic hybridisation and a panel of single locus probes. British Journal of Cancer 2003; 89: 1530-1537.
35. Khan J, Parsa NZ, Harada T, Meltzer PS and Carter NP. Detection of gains and losses in 18 meningiomas by comparative genomic hybridisation. Cancer Genetics and Cytogenetics 1998; 103: 95-100.
36. Ensembl Dog Genome Browser, The Wellcome Trust Sanger Institute (2007) http://www.ensembl.org/Canis_familiaris/ [accessed 9 May 2007].
37. Breen M, Hitte C, Lorentzen TD, Thomas R, Cadieu E, Sabacan L, Scott A, Evanno G, Parker HG, Kirkness EF, Hudson R, Guyon R, Mahairas GG, Gelfenbeyn B, Fraser CM, Andre C, Galibert F and Ostrander EA. An integrated 4249 marker FISH/RH map of the canine genome. BioMed Central Genomics 2004; 5: 65-75.
38. Ensembl Dog MarkerView (2007) http://www.ensembl.org/Canis_familiaris/ markerview?marker=REN59H07 [accessed 9 May 2007].
39. Hansson CM, Buckley PG, Grigelioniene G, Piotrowski A, Hellström AR, Mantripragada K, Jarbo C, Mathiesen T and Dumanski JP. Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus. BMC Genomics 2007; 8: 16.
40. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, Delattre O, Thomas G, Nordenskjold M, Collins VP, Dumanski JP and Rouleau GA. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nature Genetics 1994b; 6: 180-184.
41. Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, Louis DN, Ramesh V, Gusella JF, Wiestler OD and von Deimling A. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. American Journal of Pathology 1995; 146: 827-832.
42. Peyrard M, Fransson I, Xie YG, Han FY, Ruttledge MH, Swahn S, Collins JE, Dunham I, Collins VP and Dumanski JP. Characterization of a new member of the human beta-adaptin gene family from chromosome 22q12, a candidate meningioma gene. Human and Molecular Genetics 1994; 3: 1393-1399.
43. Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, Rempel SA, Gutierrez JA and Newsham IF. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Human and Molecular Genetics 2000; 9: 1495-1500.
44. Nunes F, Shen Y, Niida Y, Beauchamp R, Stemmer-Rachamimov AO, Ramesh V, Gusella J and MacCollin M. Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma. Cancer Genetics and Cytogenetics 2005; 162: 135-139.
45. Lindblom A, Ruttledge M, Collins VP, Nordenskjold M and Dumanski JP. Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumour progression. International Journal of Cancer 1994; 56: 354-357.
46. Maruno M, Yoshimine T, Muhammad AK, Ninomiya H and Hayakawa T. Chromosomal losses and gains in meningiomas: Comparative genomic hybridisation study of the whole genome. Neurology Research 1998; 20: 612-616.
47. Buckley PG, Jarbo C, Menzel U, Mathiesen T, Scott C, Gregory SG, Langford CF and Dumanski JP. Comprehensive DNA copy number profiling of meningioma using a chromosome 1 tiling path microarray identifies novel candidate tumor suppressor loci. Cancer Research 2005; 65: 2653-2661.
48. Willis TG, Zalcberg IR, Coignet LJ, Wlodarska I, Stul M, Jadayel DM, Bastard C, Treleaven JG, Catovsky D, Silva ML and Dyer MJ. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 1998; 91: 1873-1881.
49. Watson MA, Gutmann DH, Peterson K, Chicoine MR, Kleinschmidt-DeMasters BK, Brown HG and Perry A. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. American Journal of Pathology 2002; 161: 665-672.
50. Boström J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, Ichimura K, Collins VP and Reifenberger G. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. American Journal of Pathology 2001; 159: 661-669.
51. Rey JM, Noruzinia M, Brouillet JP, Sarda P, Maudelonde T and Pujol P. Six novel heterozygous MLH1, MSH2, and MSH6 and one homozygous MLH1 germline mutations in hereditary nonpolyposis colorectal cancer. Cancer Genetics and Cytogenetics 2004; 155: 149-151.
52. Seifert M and Reichrath J. The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: Implications for pathogenesis, progression and therapy of cancer. Journal of Molecular Histology 2006; 37: 301-307.
53. Barrett MT, Scheffer A, Ben-Dor A, Sampas N, Lipson D, Kincaid R, Tsang P, Curry B, Baird K, Meltzer PS, Yakhini Z, Bruhn L and Laderman S. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proceedings of the National Academy of Sciences USA 2004; 101: 17765-17770.
54. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM and Sherlock G. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nature Genetics 2000; 25: 25-29.
55. Bio Mart Project, European Bioinformatics Institute (2007) http://www.biomart.org/biomart/martview/ [accessed 9 May 2007].